Selected article for: "critical cohort and retrospective cohort"
Author: Hu, Qin; Xu, Yu; Xiang, Ying; Wang, Bin; Yuan, Zhiquan; Shan, Yifan; Zhang, Wenjing; Wu, Na; Xia, Tingting; Li, Chengying; Xie, Weijia; Jia, Xiaoyue; Yu, Zubin; Bai, Li; Li, Yafei
Title: Inflammation characteristics and anti-inflammation treatment with tocilizumab of severe/critical COVID-19 patients: A retrospective cohort study
  • Cord-id: sa9m0qu4
  • Document date: 2021_5_17
    • ID: sa9m0qu4
    Snippet: The efficacy of tocilizumab on the prognosis of severe/critical COVID-19 patients is still controversial so far. We aimed to delineate the inflammation characteristics of severe/critical COVID-19 patients and determine the impact of tocilizumab on hospital mortality. Here, we performed a retrospective cohort study which enrolled 727 severe or critical inpatients (≥18 years old) with laboratory-confirmed COVID-19 from Huoshenshan Hospital (Wuhan, China), among which 50 patients received tociliz
    Document: The efficacy of tocilizumab on the prognosis of severe/critical COVID-19 patients is still controversial so far. We aimed to delineate the inflammation characteristics of severe/critical COVID-19 patients and determine the impact of tocilizumab on hospital mortality. Here, we performed a retrospective cohort study which enrolled 727 severe or critical inpatients (≥18 years old) with laboratory-confirmed COVID-19 from Huoshenshan Hospital (Wuhan, China), among which 50 patients received tocilizumab. This study confirmed that most recovered patients manifested relatively normal inflammation levels at admission, whereas most of the deceased cases presented visibly severe inflammation at admission and even progressed into extremely aggravated inflammation before their deaths, proved by some extremely high concentrations of interleukin-6, procalcitonin, C-reactive protein and neutrophil count. Moreover, based on the Cox proportional-hazards models before or after propensity score matching, we demonstrated that tocilizumab treatment could lessen mortality by gradually alleviating excessive inflammation and meanwhile continuously enhancing the levels of lymphocytes within 14 days for severe/critical COVID-19 patients, indicating potential effectiveness for treating COVID-19.

    Search related documents:
    Co phrase search for related documents
    • acute ards respiratory distress syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and lymphocyte count lymphocyte ratio: 1, 2, 3, 4
    • acute ards respiratory distress syndrome and lymphocyte ratio: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and lymphocyte ratio level: 1
    • admission lymphocytopenia present and lymphocyte count: 1
    • admission lymphocytopenia present and lymphocytopenia present: 1, 2, 3, 4, 5, 6
    • admission test and lopinavir ritonavir: 1, 2, 3
    • admission test and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • admission test and lymphocyte count increase: 1
    • admission test and lymphocyte count lymphocyte ratio: 1, 2
    • admission test and lymphocyte ratio: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • admission test and lymphocyte ratio level: 1
    • admission test and lymphocytopenia present: 1
    • lopinavir ritonavir and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • lopinavir ritonavir and lymphocyte ratio: 1, 2, 3, 4